## Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

## Listing of the Claims:

Claim 1 (currently amended): A compound of formula (I):

wherein:

R<sup>1</sup> is phenyl-{optionally substituted by halogen, hydroxy, eyano, C<sub>1-4</sub> alkyl (itself optionally mono-substituted by eyano, hydroxy or phenyl), C<sub>1-4</sub> alkoxy (itself optionally substituted by tetrahydrofuranyl), CF<sub>3</sub>, OCF<sub>3</sub>, methylenedioxy, C(O)R<sup>3</sup>, S(O)<sub>2</sub>R<sup>4</sup> phenyl (itself optionally substituted by halogen) or tetrahydrofuranyloxy}, naphthyl, pyridinyl, 1,2,3,4-tetrahydropyrimidin-2,4-dione-yl (optionally substituted by C.sub.1-4 alkyl) or, tetrahydrothienyl or phenyl, wherein said phenyl is substituted by 0, 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, methylenedioxy, C(O)R<sup>3</sup>, S(O)<sub>2</sub>R<sup>4</sup>, phenyl, phenoxy and tetrahydrofuranyloxy;

R<sup>2</sup> is aminopyridinyl, aminothiazolyl or 3-azabicyclo[3.2.1]octyl;

R<sup>3</sup> is hydroxy, C<sub>1-4</sub> alkoxy (itself optionally substituted by phenyl (itself optionally substituted by halogen) or pyridinyl), NR<sup>5</sup>R<sup>6</sup> or an N-linked 5- or 6-membered heterocyclic ring, wherein said N-linked 5- or 6-membered heterocyclic ring is substituted by 0, 1 or 2 substituents selected from hydroxy, oxo, C<sub>1-4</sub> alkyl, CO<sub>2</sub>(C<sub>1-4</sub> alkyl) and phenyl; {unsubstituted or mono-

- substituted by hydroxy, oxo,  $C_{1,4}$  alkyl (itself optionally substituted by hydroxy or NHphenyl),  $CO_2(C_{1,4}$  alkyl) or phenyl (itself optionally substituted by halogen);
- R<sup>4</sup> is NR<sup>7</sup>R<sup>8</sup> or an N-linked 5- or 6-membered heterocyclic ring, wherein said N-linked 5- or 6-membered heterocyclic ring is substituted by 0 or 1 substituents selected from hydroxy, oxo, C<sub>1-4</sub> alkyl, CO<sub>2</sub>(C<sub>1-4</sub> alkyl) and phenyl; or fused to a benzene ring which is optionally substituted by 0, 1 or 2 substituents independently selected from C<sub>1-4</sub> alkoxy; {unsubstituted; mono-substituted by hydroxy, oxo, C<sub>1-4</sub> alkyl (itself optionally substituted by hydroxy or NHphenyl), CO<sub>2</sub>(C<sub>1-4</sub> alkyl) or phenyl (itself optionally substituted by halogen); or fused to a benzene ring which is optionally substituted by C<sub>1-4</sub> alkoxy);
- R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are, independently, hydrogen, <u>C<sub>2-4</sub> alkenyl or C<sub>1-4</sub> alkyl</u>, wherein said <u>C<sub>1-4</sub> alkyl</u> is substituted by 0, 1 or 2 substituents selected from halogen, cyano, hydroxy, phenyl, pyridinyl, <u>CO<sub>2</sub>H and CO<sub>2</sub>(C<sub>1-4</sub> alkyl)</u>; <del>C<sub>1-4</sub> alkyl {optionally substituted by halogen, cyano, hydroxy, phenyl (itself optionally substituted by halogen or methylenedioxy), pyridinyl, <u>CO<sub>2</sub>H or CO<sub>2</sub>(C<sub>1-4</sub> alkyl)</u> I or <u>C<sub>2-4</sub> alkenyl</u>;</del>
- provided that when R<sup>2</sup> is 6-aminopyridin-3-yl then R<sup>1</sup> is substituted phenyl, naphthyl, pyridinyl, 1,2,3,4-tetrahydropyrimidin-2,4-dione-yl, (optionally substituted by C.sub.1-4 alkyl) or tetrahydrothienyl or phenyl, wherein said phenyl is substituted by 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, methylenedioxy, C(O)R<sup>3</sup>, S(O)<sub>2</sub>R<sup>4</sup>, phenyl, phenoxy and tetrahydrofuranoxy;

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

Claim 2 (currently amended): A-<u>The</u> compound of formula (I) as claimed in claim 1 wherein R<sup>1</sup> is <u>pyridinyl</u>, <u>tetrahydrothienyl</u> or <u>phenyl</u>, <u>wherein said phenyl is</u> <del>{optionally substituted by 0, 1, 2 or 3 substituted by cyano or hydroxy), C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, methylenedioxy, C(O)NH<sub>2</sub>, S(O)<sub>2</sub>NH<sub>2</sub> or <u>and phenyl</u> <del>(itself optionally substituted by halogen)}, pyridinyl or tetrahydrothienyl</del>.</del>

Claim 3 (currently amended): A-<u>The</u> compound of formula (I) as claimed in claim 1 wherein R<sup>1</sup> is <u>naphthyl</u>, <u>pyridinyl</u>, <u>tetrahydrothienyl</u> or <u>phenyl</u>, <u>wherein said phenyl</u> is substituted by 0, 1, 2

or 3 substituents selected from {optionally substituted by halogen, hydroxy, cyano, C<sub>1-4</sub> alkyl (itself optionally mono substituted by cyano, hydroxy or phenyl), C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, methylenedioxy, phenoxy (itself optionally substituted by halogen), tetrahydrofuranyloxy or and tetrahydrofuranylmethoxy}, naphthyl, pyridinyl or tetrahydrothienyl.

Claim 4 (currently amended): A-<u>The</u> compound of formula (I) as claimed in claim 1 wherein R<sup>1</sup> is <u>tetrahydrothienyl</u> or phenyl, <u>wherein said phenyl is substituted</u> <del>{substituted by 0, 1, 2 or 3 substituted from halogen, hydroxy, cyano, C<sub>1-4</sub> alkyl <del>(itself optionally mono-substituted by cyano or hydroxy), C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or and methylenedioxy<del>} or tetrahydrothiophenyl</del>.</del></del>

Claim 5 (currently amended): A-The compound of formula (I) as claimed in claim 1, 2, 3 or 4 wherein R<sup>2</sup> is 6-aminopyridin-3-yl, 2-aminothiazol-5-yl or 3-azabicyclo[3.2.1]oct-8-yl.

Claim 6 (currently amended): A-The compound of formula (I) as claimed in claim 1, 2, 3 or 4 wherein R<sup>2</sup> is 6-aminopyridin-3-yl.

Claim 7 (cancelled)

Claim 8 (currently amended): A pharmaceutical formulation containing a compound according to any one of claims 1 to 6 claim 1 as active ingredient in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claims 9-10 (cancelled)

Claim 11 (withdrawn and currently amended): A method for treatment or prophylaxis of treating conditions where inhibition of carboxypeptidase U is beneficial, comprising administering to a mammal, including man, in need of such treatment an effective amount of a compound as claimed in claim 1.

## Claim 12 (cancelled).

```
Claim 13 (new): A compound selected from
```

- 2-[(6-aminopyridin-3-yl)methyl]-5-(1,1'-biphenyl-3-yl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-(1-naphthyl)pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-cyanophenyl)-3-mercaptopentanoic acid;
- 5-[3-(Aminocarbonyl)phenyl]-2-[(6-aminopyridin-3-yl)methyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[2-fluoro-4-(trifluoromethyl)pheny-l]-3-mercaptopentanoic acid:
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-chlorophenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(1,3-benzodioxol-5-yl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-pyridin-2-ylpentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-(3,4,5-triethoxyphenyl)pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-pyridin-3-ylpentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[4-(cyanomethyl)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(2-hydroxyphenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[4-(aminosulfonyl)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-(4-methoxyphenyl)pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(4-hydroxyphenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-[4-(trifluoromethoxy)phenyl]-pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-(tetrahydro-2-thienyl)-pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[3-(hydroxymethyl)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[2-(2,4-dichlorophenoxy)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3,5-dimethylphenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-(4-propylphenyl)pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(4-benzylphenyl)-3-mercaptopentanoic acid;
- 2-[(2-Amino-1,3-thiazol-5-yl)methyl]-3-mercapto-5-phenylpentanoic acid;

- 2-(3-Azabicyclo[3.2.1]oct-8-ylmethyl)-3-mercapto-5-phenylpentanoic acid;
- 2-[(6-aminopyridin-3-yl-)methyl]-3-mercapto-5-(3-{[methyl(2-phenylethyl)amino]carbonyl}phenyl)pentanoic acid;
- 3-[5-(6-Aminopyridin-3-yl)-4-carboxy-3-mercaptopentyl]benzoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[3-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-{3-[(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]phenyl}-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-{3-[(2-pyridin-2-ylethoxy)carbonyl]phenyl}pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[2-(2,6-dichlorophenyl)ethoxy]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[3-(ethoxycarbonyl)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[(2-fluoroethyl)amino]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-{3-[(dimethylamino)carbonyl]phenyl}-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-{3-[(vinylamino)carbonyl]phenyl}pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-[3-({[2-(1,3-benzodioxol-5-yl) ethyl]amino}carbonyl)phenyl]-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-{3-[(dibenzylamino)carbonyl]phenyl}-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-3-{[(2-hydroxyethyl) (methyl)amino]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-{3-[(3-hydroxypyrrolidin-1-yl)carbonyl]phenyl}-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[4-(4-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)-3-mercaptopentanoic acid;

- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[benzyl(methyl)amino]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-[3-(pyrrolidin-1-ylcarbonyl)phenyl]pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[4-(ethoxycarbonyl)piperidin-1-yl]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[4hydroxymethyl)piperidin-1-yl]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-{3-[(3-oxopiperazin-1-yl)carbonyl]phenyl) pentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[benzyl(3-ethoxy-3-oxopropyl)amino]carbonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[(cyanomethyl)(methyl)amino]-sulfonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-5-(3-{[(2S)-2-(anilinomethyl)pyrrolidin-1-yl]sulfonyl}phenyl)-3-mercaptopentanoic acid;
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-{3-[(methylamino)sulfonyl]-phenyl}pentanoic acid:
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-(3-{[methyl(2-phenylethyl) amino]sulfonyl}phenyl)pentanoic acid;
- 2-[(6-aminopyridin-3-yl)methyl]-3-mercapto-5-[3-(tetrahydrofuran-3-yloxy)phenyl]pentanoic acid; and
- 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-[3-(tetrahydrofuran-3-ylmethoxy)-phenyl]pentanoic acid,
- or a pharmaceutically acceptable salt thereof.